Peter E.Devlin


New York + 1.212.326.3978

For over a decade, Peter Devlin has advised clients in connection with transformative financing transactions and day-to-day disclosure and corporate governance matters.

Peter advises companies and financial institutions across a wide range of public and private securities offerings, including initial public offerings and other equity offerings (both primary and secondary); investment-grade, convertible, and high yield debt offerings; and exchange offers, tender offers, and consent solicitations. He has significant experience advising domestic and international clients on securities laws, corporate governance matters, SEC reporting requirements, and stock exchange rules and regulations. Peter often counsels emerging companies on the legal and practical aspects of the public offering process in the United States.

Peter has worked with many types of issuers, ranging from emerging companies to multinational corporations, on transactions across many different industries, including agricultural technology, biotechnology, financial technology, financial services, insurance, transportation, shipping, consumer products, telecommunications, and education.

Peter is an advisory board member of the School of Science at Manhattan College.


  • TotalEnergies completes PIPE investment in NextDecade Corporation and investment in $18.5 billion Rio Grande LNG ProjectJones Day represented TotalEnergies in connection with its PIPE investment in NextDecade Corporation and investment in the Rio Grande LNG (RGLNG) Project, a planned natural gas liquefaction project in South Texas.
  • Cibus combines with CalyxtJones Day advised Cibus Global, LLC (“Cibus”), a San Diego based leader in precision gene editing in agriculture, in connection with an all-stock merger with Calyxt, Inc. (NASDAQ: CLXT), under which Cibus and Calyxt created an industry-leading company that combines two pioneers in agriculture-based gene editing and establishes one of the world’s most sophisticated facilities for trait development and plant breeding.
  • Investor Group of Apollo, J.F. Lehman & Company and Hill City Capital acquires Atlas Air Worldwide for $5.2 billionJones Day advised J.F. Lehman & Company and Hill City Capital in their participation in a consortium with Apollo for the acquisition of Atlas Air Worldwide (NASDAQ: AAWW) in an all cash transaction with an enterprise value of approximately $5.2 billion.
  • Accelmed Partners leads $30 million private placement of Common Stock issued by Minerva Surgical, Inc.Jones Day represented Accelmed Partners in connection with its purchase of $30 million of Common Stock in a private placement issued by Minerva Surgical, Inc., granting Accelmed Partners a controlling stake in Minerva Surgical.
  • MassMutual and its affiliate invest in newly formed limited partnership formed for purpose of acquiring redeemable Common Stock of SPACsJones Day represented Massachusetts Mutual Life Insurance Company and its affiliate in connection with an investment, in the form of a term loan and equity contribution, to a newly formed limited partnership formed for the purpose of acquiring and trading in redeemable Common Stock issued by Special Purpose Acquisition Companies (SPACs).
  • Koch invests in Compass MineralsJones Day is advising Koch Minerals & Trading, LLC in connection with its $252 million investment in the common stock of Compass Minerals International, Inc. (NYSE:CMP).
  • GE Aerospace sells revolutionary hydrogen and fuel agnostic generator technology to HyliionJones Day advised GE Aerospace, part of GE, a world leader in the sale of metal additive technologies and manufacturing, in the sale of a new hydrogen and fuel agnostic capable generator ("KARNO") to Hyliion Holdings Corp., a leader in electrified powertrain solutions for Class 8 semi-trucks.
  • EDAP completes follow-on public offering of American Depositary SharesJones Day represented EDAP TMS, a global leader in robotic energy-based therapies, in connection with its follow-on public offering of 3,066,667 American Depositary Shares (ADSs) on the Nasdaq Global Market.
  • GenScript Biotech Corporation completes US$402 million follow-on offering by Legend Biotech CorporationJones Day represented GenScript Biotech Corporation in connection with a US$402 million follow-on offering by its Nasdaq-subsidiary Legend Biotech Corporation (NASDAQ: LEGN).
  • Koch Equity Development portfolio company, Getty Images, completes business combination with SPAC, CC Neuberger Principal Holdings IIJones Day acted as counsel to Koch Equity Development LLC, a subsidiary of Koch Industries, Inc. and investor in Getty Images, in the business combination agreement with CC Neuberger Principal Holdings II (NYSE: PRPB), a publicly traded special purpose acquisition company.
  • Deezer merges with and into I2PO S.A.Jones Day advised Deezer S.A. in the context of the SPAC transaction whereby Deezer S.A. merged with and into I2PO S.A., a French SPAC listed on the professional segment of the regulated market of Euronext Paris and the related PIPE financing.
  • Sanofi announces carve-out creating EUROAPI and spin-off of approximately 58% of shares to its shareholdersJones Day advised Sanofi in the carve out creating EUROAPI (a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients) and the listing of this entity on Euronext Paris and the placement of 12% to the French State (through French Tech Souveraineté) for a price of up to €150 million.
  • Calyxt completes $10.9 million placement of Common Stock and WarrantsJones Day represented Calyxt, Inc. in connection with the placement to an institutional investor in an underwritten offering of 3,880,000 shares of its Common Stock, pre-funded warrants to purchase up to 3,880,000 shares of its Common Stock, and Common Warrants to purchase up to 7,760,000 shares of its Common Stock.
  • GenScript Biotech Corporation completes US$344.6 million follow-on offering by Legend Biotech CorporationJones Day represented GenScript Biotech Corporation in connection with its US$344.6 million follow-on offering by its NASDAQ-subsidiary Legend Biotech Corporation.
  • Neura acquired by Otonomo TechnologiesJones Day advised Neura, Inc., a leader in AI-powered mobility intelligence, in its acquisition by Otonomo Technologies Limited.
  • Calyxt establishes $50 million at-the-market equity programJones Day represented Calyxt, Inc., a plant-based technology company, in connection with the establishment of an at-the-market offering program for up to $50 million of its Common Stock.
  • GenScript Biotech and its subsidiaries Legend Biotech and ProBio Cayman complete US$1.07 billion investment by Hillhouse CapitalJones Day represented GenScript Biotech Corporation (“GenScript Biotech”), its controlling shareholder GenScript Corporation, and its two subsidiaries Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) and Probio Technology Limited (“Probio Cayman”) in connection with a US$1.07 billion investment by Hillhouse Capital.
  • Bpifrance sells interests in HalioDx to Veracyte, Inc.Jones Day represented Bpifrance in the sale of its interests in HalioDx, a French private biotech company specialized in immune-based diagnostic products and services, as part of the €260 million sale of HalioDx to Veracyte, Inc., a U.S. global genomic diagnostics company listed on the Nasdaq.
  • Victorian Plumbing Group completes largest to date IPO on London Stock Exchange’s AIM marketJones Day represented Victorian Plumbing Group plc, the UK’s leading online specialist bathroom brand and the second largest retailer of bathroom products in the UK, in connection with its £850 million IPO on the London Stock Exchange’s AIM market.
  • KeyBanc Capital Markets-led syndicate completes $1.2 billion Senior Notes offering, including issuance of SOFR Senior Notes, by KeyBankJones Day represented KeyBanc Capital Markets Inc.; Credit Suisse Securities (USA) LLC; Deutsche Bank Securities Inc.; RBC Capital Markets, LLC; Wells Fargo Securities, LLC; and the other agents, in connection with KeyBank National Association’s offering of $800 million aggregate principal amount of Fixed-to-Floating Compound SOFR Senior Bank Notes due June 14, 2024 and $400 million aggregate principal amount of Floating Compound SOFR Senior Bank Notes due June 14, 2024 in a transaction exempt from registration pursuant to Section 3(a)(2) of the Securities Act of 1933.
  • Speaking Engagements

    • May 10, 2018
      Blockchain for Lawyers, The New York City Bar Association
    • October 15, 2018
      Virtual Token Issuance and Management, panelist, IBM IT Services Legal Summit